Organon & Co. (OGN) Scheduled to Post Quarterly Earnings on Thursday

Organon & Co. (NYSE:OGN - Get Free Report) will be posting its quarterly earnings results before the market opens on Thursday, October 31st. Analysts expect Organon & Co. to post earnings of $0.94 per share for the quarter. Organon & Co. has set its FY 2024 guidance at EPS.Individual that are interested in registering for the company's earnings conference call can do so using this link.

Organon & Co. (NYSE:OGN - Get Free Report) last posted its quarterly earnings data on Tuesday, August 6th. The company reported $1.12 earnings per share for the quarter, topping analysts' consensus estimates of $1.08 by $0.04. The company had revenue of $1.61 billion during the quarter, compared to analysts' expectations of $1.61 billion. Organon & Co. had a negative return on equity of 840.29% and a net margin of 15.76%. The firm's revenue for the quarter was down .1% on a year-over-year basis. During the same period last year, the firm earned $1.31 EPS. On average, analysts expect Organon & Co. to post $4 EPS for the current fiscal year and $4 EPS for the next fiscal year.

Organon & Co. Price Performance

Shares of OGN traded up $0.01 during trading hours on Thursday, reaching $17.22. The company had a trading volume of 1,990,517 shares, compared to its average volume of 2,166,577. The firm has a 50 day simple moving average of $19.83 and a 200-day simple moving average of $20.12. Organon & Co. has a 12-month low of $10.84 and a 12-month high of $23.10. The company has a current ratio of 1.64, a quick ratio of 1.17 and a debt-to-equity ratio of 60.05. The company has a market capitalization of $4.43 billion, a price-to-earnings ratio of 4.43, a PEG ratio of 0.78 and a beta of 0.84.

Organon & Co. Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Thursday, September 12th. Stockholders of record on Friday, August 16th were issued a $0.28 dividend. The ex-dividend date of this dividend was Friday, August 16th. This represents a $1.12 dividend on an annualized basis and a dividend yield of 6.50%. Organon & Co.'s dividend payout ratio (DPR) is 28.79%.

Analyst Upgrades and Downgrades

OGN has been the topic of several research analyst reports. Evercore ISI raised shares of Organon & Co. to a "strong-buy" rating in a research report on Wednesday, September 18th. JPMorgan Chase & Co. cut Organon & Co. from a "neutral" rating to an "underweight" rating and increased their target price for the company from $18.00 to $20.00 in a research note on Friday, September 6th.

About Organon & Co.

Organon & Co develops and delivers health solutions through a portfolio of prescription therapies and medical devices within women's health in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, a daily pill used to prevent pregnancy; Marvelon, progestin and estrogen used as daily pills to prevent pregnancy; Follistim AQ, used to promote the development of multiple ovarian follicles in assisted reproduction technology procedures; Elonva, an ovarian follicle stimulant; Ganirelix Acetate Injection, an injectable antagonist; and Jada, for abnormal postpartum uterine bleeding or hemorrhage.